Title of Invention	STABLE CRYSTAL MODIFICATIONS OF DOTAP CHLORIDE
Abstract	The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R.S)-, (2S)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.

Full Text

W0 2006/056312 PCT/EP2005/011874 Stable crystal modifications of DOTAP chloride The present invention relates to enantiomerically pure DOTAP chloride and crystal modifications of racemic and enantiomerically pure DOTAP chloride, to a process for the preparation thereof, and to the use thereof for the preparation of pharmaceutical compositions. DOTAP chloride above and below denotes N,N,N-trimethyl-2,3-bis[[(9Z)- 1-oxo-9-octadecenyl]oxy]-1-propanaminium chloride, also known as (Z,Z)-N,N,N-trimethyl-2,3-bis[(1-oxo-9-octadecenyl)oxy]-1-propanami- nium chloride or 1,2-dioleoyloxy-3-trimethylammonium propane chloride, and the hydrates thereof. CAS numbers: 132172-61 -3 and 477274-39-8 (racemate), 197974-73-58 (racemate, monohydrate) 428506-51-8 (2S form), 328250-28-8 (2R form) Liposomes are synthetic multilayered vesicles (spherically self-contained membranes) comprising ambiphilic substances, usually natural lipids, into which both hydrophilic substances can be encapsulated into the aqueous interior, and also lipophilic substances can be incorporated into the inside of the lipid membrane. They are employed in particular in cosmetics and in medicine, especially in dermatology. Here, in particular vitamins, coenzymes, skin-care agents and sunscreens are embedded. Liposomes are generally applied topi- cally. However, liposomes are increasingly achieving further importance in pharmaceutical technology, since parenteral application of liposomes WO 2006/056312 PCT/EP2005/011874 -2- enables more specific organ distribution to be achieved than if the active compounds are used in freely dissolved form. If DNA, RNA or proteins are incorporated, lipoplexes are obtained. Addition of oils and the use of high-pressure homogenisers enables the formation of so-called nanoparticles (nanoparts) to be forced from lipo- somes. These are particles of approximately the same size as liposomes, but which do not have a water phase, but instead an oil phase in their interior. They are particularly suitable for the encapsulation of lipophilic substances. Microemulsions are colloidally disperse, single-phase systems compris- ing aqueous, lipid-like and surfactant components. They have a particle size of 1-500 nm and behave in a similar manner to liquids. Especially in connection with peptidic active compounds, nucleotides, vaccines and other biopharmaceuticals, which normally have poor solu- bility, the solubilising effect has very great importance in the case of the applications described above. In addition, degradation of the active compounds in the body can be slowed and a sustained-release effect achieved in this way. DOTAP chloride belongs to the class of cationic lipids. In contrast to naturally occurring phospholipids, these do not have a zwitterionic char- acter. Liposomes comprising cationic lipids, alone or combined with phospholipids or other lipid-like compounds, have a positively charged surface. This gives rise to high affinity to cells which have a negatively charged surface on the outside, for example endothelial cells. Particularly important, however, is the ability of DOTAP-based and other cationic liposomes and lipoplexes to penetrate into cells and thus to transport the active compounds incorporated therein into the interior of the cell (transfection). WO 2006/056312 PCT/EP2005/011874 -3- All these properties make DOTAP chloride very interesting for cancer therapy too. These properties give rise to the possibility of applying con- ventional cytostatic agents incorporated in cationic DOTAP liposomes. The transfection properties of DOTAP chloride and other DOTAP salts, such as, for example, the acetate, bromide, dihydrogenphosphate, hydrogensulfate, iodide, mesylate, methylsulfate, trifluoroacetate, sulfate or disulfate and triflate, are adequately known from the literature. DOTAP dihydrogenphosphate and DOTAP mesylate are only mentioned as racemate in the literature. All other salts mentioned above are each mentioned as racemate and as 2S-enantiomer, and in addition the 2R- enantiomers of the chloride and methylsulfate are mentioned. In some in-vitro studies, other salts, such as, for example, DOTAP methylsulfate, have achieved better transfection rates than DOTAP chlo- ride. Used in vivo, however, anion exchange at the liposome surface takes place in the living body, meaning that the advantages of other salts do not arise here. Especially on medical use in humans in particular for parenteral application, DOTAP salts with physiologically acceptable anions, such as, for example, the corresponding chloride or the acetate, are therefore preferred. Medical, in particular parenteral applications make the highest demands of the quality and purity of the active compounds and adjuvants used. There are therefore very strict regulations on the part of the authorities with respect to the preparation, reproducibility of preparation and by- product profile of these compounds. In the case of substances used par- enterally, microbiological contamination by pathogenic microorganisms and endotoxins must, in addition, be strictly avoided and controlled. DOTAP chloride and other DOTAP salts are extremely unstable and are therefore difficult per se to prepare in an acceptable purity so that they are suitable for use for the preparation of a medicament formulation. WO 2006/056312 PCT/EP2005/011874 -4- Like all lipids which carry oleic acid radicals, such as, for example, the natural phospholipids DOPC and DOPE, all DOTAP salts are very sensi- tive to oxidation. However, the oxidation products of unsaturated fatty acid derivatives generally have high toxicity. Suitable preparation and purification methods are required here. DOTAP acetate, for example, is in the form of a high-boiling oil and industrially can therefore only be obtained with great difficulty in adequate quality. The conventional methods of overcoming the instability, such as, for ex- ample, the addition of antioxidants in the form of ascorbic acid or reduced L-glutathione, greatly restrict the general usability of DOTAP chloride since interactions with the active compounds to be embedded later can- not be excluded. Complete exclusion of oxygen during the preparation, storage and use is virtually impossible or can only be facilitated with very great effort. DOTAP chloride is commercially available only as a chloroform solution or as an amorphous solid. In addition to its oxidation sensitivity, amorphous DOTAP chloride is also extremely hygroscopic and deliquesces within an extremely short time at normal atmospheric humidity levels to give a greasy film. This makes handling of this compound much more difficult. Thus, the manufacturer of amorphous DOTAP chloride generally recom- mends storage under protective gas at -20°C and only guarantees a shelf life of about 6 months. The literature only reveals various synthetic routes for the preparation of amorphous, racemic DOTAP chloride: Eibel and Unger, DE4013632A1, outline the synthesis of DOTAP chloride from DOTAP bromide by ion exchange in the chloro- form/methanol/aqueous HCI solvent system followed by purification by means of chromatography. DOTAP bromide is obtained in advance in situ from 1-bromo-2,3-dioleoyloxypropane. WO 2006/056312 PCT/EP2005/011874 -5- Leventis and Silvius, Biochim. Biophys. Acta, 1023 (1990) 124-132, report on the synthesis of DOTAP chloride from DOTAP iodide by ion exchange in the two-phase solvent/NaCI solution system. DOTAP iodide is obtained in advance by methylation of the corresponding dimethyl- amino compound by means of methyl iodide. Nantz et al., Biochim. Biophys. Acta, 1299 (1996) 281-283, J. Med. Chem. 40 (1997) 4069-4078, describe the synthesis of DOTAP chloride by non-aqueous ion exchanger chromatography. The desired compound is obtained by evaporation of the eluate. Feigner et al., US 5,264,618, carry out the methylation of the correspond- ing dimethylamino compound directly to DOTAP chloride by means of methyl chloride. They apparently obtain a yellow wax by crystallisation from acetonitrile at -20°C. However, DOTAP chloride is virtually insoluble in acetonitrile at room temperature. Attempts to reproduce this so-called crystallisation gave only amorphous material through solidification of the oily substance obtained from hot solution on cooling. The fact that this is not a crystallisation is also evident from the fact that the authors appar- ently do not achieve a purification effect and have to purify the substance by chromatography. Consequently, neither synthetic routes for the preparation of the two enantiomeric DOTAP chlorides nor characteristic properties thereof are known to date. Although Chemical Abstracts has assigned numbers for the two enantiomers, the corresponding publications describe exclusively work with racemic DOTAP chloride. In particular if the compounds are intended for parenteral use, a prepara- tion which includes treatment with ion exchanger resin is extremely problematical in view of possible microbiological contamination, since corresponding resins are an ideal nutrient medium for bacteria and even after they have been killed, a risk of contamination by endotoxins still remains. WO 2006/056312 PCT/EP2005/011874 -6- The object of the present invention is therefore to provide DOTAP chlo- ride salts and hydrates in high purity and with adequate chemical and physical stability. A further object of the present invention is to provide these salts with long shelf lives, enabling them to be used for the prepa- ration of pharmaceutical formulations. There continues to be a great demand for a reproducible process for the preparation of stable forms of DOTAP chloride salts and hydrates which can be carried out on an industrial scale. Enantiomerically pure DOTAP chloride can be obtained from enantio- merically pure starting materials analogously to the processes described for the racemate, i.e. via (R or S)-1-chloro-2,3-dioleoyloxypropane, via (R or S)-1-LG-2,3-dioleoyloxypropane and ion exchange (LG=leaving group) or via (R or S)-1-dimethylamino-2,3-dioleoyloxypropane. A further preparation method which may be mentioned is racemate reso- lution of racemic DOTAP chloride. By means of experiments, it has now been found, surprisingly, that both racemic and also enantiomerically pure, crystalline DOTAP chloride can be obtained in a simple manner with high chemical purity and excellent stability. The crystalline products obtained in this way have virtually unlimited stability at room temperature under protective gas. They are therefore suitable as constituent or as starting material for the prepara- tion of medicament forms. The present invention accordingly relates to enantiomerically pure DOTAP chloride and stable crystal modifications of racemic and enantio- merically pure DOTAP chloride. The stable crystal modifications can be in crystalline and partially crystal- line form. They have a never hitherto achieved purity of > 98% together with a never hitherto achieved stability of > 98% in relation to the starting value after storage for 12 months with exclusion of air at 25°C and 60% relative atmospheric humidity, (see in this respect Table 1). The DOTAP WO 2006/056312 PCT/EP2005/011874 -7- chloride crystal modifications have a content of less than 1 equivalent of water or solvent of crystallisation per equivalent of DOTAP chloride. The racemic DOTAP chloride crystal modifications exist, for example, in three different crystal modifications (type I, type II, and type III) and ex- hibit moderately sharp bands in powder X-ray diffraction measurements (see in this respect Fig. 1 to Fig. 3 and Table 2). Selected 2 theta values for the various crystal modifications are 12.6, 19.5, 20.2, 21.5 and 25.2 (type I); or 3.3, 4.9, 19.3, 20.0 and 23.5 (type II); or 2.8, 5.8, 20.0, 21.2 and 25.1 (type III). Enantiomerically pure DOTAP chlorides are likewise obtained in crystal- line form. Selected 2 theta values for the crystal modification found are 12.8, 19.4, 19.8, 20.2, and 21.5 (type IV, see in this respect Fig. 4). The enantiomers are optically active. Thus, (2S)-DOTAP chloride has an optical rotation of-2.12°, (2R)-DOTAP chloride has an optical rotation of +2.12° ([a]D at 20°C, 1% solution in dichloromethane). The invention furthermore relates to a process for the preparation of DOTAP chloride crystal modifications which is characterised in that DOTAP chloride is crystallised from an aprotic medium. The aprotic medium used for this purpose can be aprotic solvents or mixtures thereof. The aprotic medium may also comprise protic solvents, such as, for example, water, in small amounts. In exceptional cases, 25% by weight of protic solvents may also be present under suitable conditions. The crystallisation of the DOTAP chlorides can be carried out here directly from the reaction solution without prior purification. Likewise, crystalline DOTAP chloride can be obtained by recrystallisation of amorphous, par- tially crystalline or crystalline material. Suitable aprotic solvents are, in particular, ethers, such as, for example, tetrahydrofuran, methyltetrahydrofuran, dioxane, diethyl ether, dipropyl ether, WO 2006/056312 PCT/EP2005/011874 -8- diisopropyl ether and methyl tert-butyl ether, ketones, such as, for example, acetone and 2-butanone, methyl isobutyl ketone, methyl isopropyl ketone, nitriles, such as, for example, acetonitrile, and esters, such as, for example, ethyl formate, methyl acetate, ethyl ace- tate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, dimethyl carbonate, diethyl carbonate and 1,3-di- oxolidin-2-one. These solvents may in each case be used in pure form or in the form of a mixture, i.e. it is possible both to use the various aprotic solvents in a group in the form of a mixture and also to employ aprotic solvent types inn the form of a mixture with one another. As already indicated above, protic solvent additions may be present in the aprotic solvent or solvent mixture used. Protic solvent additions of this type can typically consist of the following solvents: alcohols, such as, for example, methanol, ethanol, n-propanol, isopropa- nol, n-butanol, isobutanol, 2-butanoi, tert- butanol, 3-methyl-1-butanol and ethylene glycol, methoxyethanol, ethoxyethanol, or water. The protic solvent additions may in turn be additions of the pure solvents or of mixtures of these protic solvents. The crystallisation of the DOTAP chloride modifications is generally achieved specifically by slow cooling of the prepared solution to tem- peratures below 30°C. The formation of the crystals is carried out either spontaneously or by inoculation with the corresponding DOTAP chloride crystal modification. WO 2006/056312 PCT/EP2005/011874 -9- The various DOTAP chloride crystal modifications can be converted into one another. The conversions can be achieved by heat treatments of the isolated crystal modifications at elevated temperature or by extended stirring of their suspensions under crystallisation conditions. The use of amorphous or partially crystalline DOTAP chloride as starting material for the recrystallisation gives, by the process described, essen- tially crystalline DOTAP chlorides of never hitherto achieved purity to- gether with never hitherto achieved stability. The invention also relates to the use of crystalline DOTAP chlorides for the preparation of medicament formulations since the crystalline DOTAP chlorides have excellent stability in solid form under the stated conditions and have constant and very good quality for a virtually unlimited time. In addition, enantiomerically pure DOTAP chlorides have different physi- cal properties to the racemate, in particular in combination with chiral compounds, such as the phospholipids or cholesterol. The novel properties found for the enantiomerically pure DOTAP chlo- rides can advantageously be utilised, alone or in combination with suit- able phospholipids, cholesterol and derivatives thereof, to provide novel liposome grades which, compared with conventional forms, on the one hand represent closer packings of the lipids and on the other hand have a more uniform structure. Thus, liposomes prepared from the pure enantiomers exhibit a 5°C higher principal phase transition temperature compared with the liposomes comprising racemic DOTAP chloride. This is a measure of the packing density. Liposomes comprising DOTAP chloride enantiomers therefore also have reduced leaking of the compound incorporated in them. This has the consequence that liposomes charged with pharmaceutically active compounds will release active compounds in a delayed manner in interaction with the metabolism in the human or animal body. In particu- lar, sensitive active compounds can thus advantageously be transported WO 2006/056312 PCT/EP2005/011874 - 10- in a more specific manner to the desired site or organ where the medi- cament action is desired. The DOTAP chloride enantiomers also exhibit, in particular in combina- tion with chiral lipids, such as phospholipids, cholesterol and derivatives thereof, transfection properties which differ cell-line-specifically. For the preparation of these novel liposomes, it is possible for the person skilled in the art specifically to select a form or a certain mixing ratio of the DOTAP chlorides thus provided in order to prepare liposomes having certain novel properties. The invention consequently furthermore also relates to the pharmaceuti- cal compositions resulting from the use of the DOTAP chloride forms claimed. Pharmaceutical compositions of this type can comprise the crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride together with other pharmaceutical active compounds and known adjuvants usu- ally employed in medicament preparation, as well as one or more sol- vents. These pharmaceutical compositions can, for example, be in the form of liposomes, lipoplexes, microemulsions and nanoparticles and include, for example, an active compound from the group of the peptides, nucleo- tides, vaccines or cytostatic agents. The present description enables the person skilled in the art to apply the invention in a comprehensive manner. In addition, the following examples serve for better understanding and for illustration of possible variants of the invention. These examples should therefore in no way be regarded as restrictive. All temperatures mentioned in the following examples are indicated in degrees Celsius. Unless stated otherwise, content data are given as % by weight. WO 2006/056312 PCT/EP2005/011874 -11- Examples for illustrating the invention Example 1 Stabilities In order to determine the stability of crystalline DOTAP chlorides, the substances are stored together with comparative samples at 25°C and 60% relative humidity with exclusion of air. The remaining content of DOTAP chloride is measured at periodic intervals and quoted in com- parison to the initial value. The purity and content of DOTAP chloride are determined by means of HPLC. For type I, the following values are found: The stability determination can be repeated at any desired time, the val- ues indicated in Table 1 are reproducible. Table 1: (R,S)-DOTAPchloridecrystalline type I Exposure time in months 0 1 2 3 6 12 Area-% 100% 100.0% 100.0% 100.0% 100.0% 100.0% % by weight 98.6% 97.% 97.9% 97.2% 98.2% 98.7% Example 2 [Powder X-ray diagrams] For characterisation of the structural properties (crystal modifications) of crystalline DOTAP chlorides, powder X-ray diagrams (diffraction spectra) of these substances are recorded. WO 2006/056312 PCT/EP2005/011874 - 12- Crystalline DOTAP chlorides give spectra with moderately sharp bands which have relatively good resolution for lipids. The spectra indicate high crystalline contents. No amorphous fractions are visible under the polar- ising microscope. Examples of spectra are shown in Fig. 1 (type I), Fig. 2 (type II), Fig. 3 (type III) and Fig. 4 (type IV). For comparison, a spectrum of a commercially available, amorphous sample is shown in Fig. 5 (amorphous). Table 2 lists selected 2 theta values for the various crystal modifications of racemic and enantiomerically pure DOTAP chlorides: Table 2: Type Selected 2 theta values TypeTypeType IIIIII racemic 12.6, 19.5, 20.2, 21.5 and 25.23.3,4.9, 19.3, 20.0 and 23.52.8, 5.8, 20.0, 21.2 and 25.1 Type IV enantiomericallypure 12.8, 19.4, 19.8, 20.2, and 21.5 Example 3 Principal phase transition temperatures Differential scanning caliometry (DSC) measurements are carried out on multilamellar liposomes in water. Liposomes are prepared by the thin-film method from the calculated amounts of racemic or enantiomerically pure DOTAP chloride. The lipid concentration here is in each case 0.1 g/ml. Suitable amounts of these dispersions are then introduced into sealable aluminium crucibles and WO 2006/056312 PCT/EP2005/011874 - 13- measured using a 204 Phoenix calorimeter (Netzsch, Selb, Germany). In each case, three successive heating/cooling runs from -50°C to +20°C are carried out at 1°C/min. For all three DOTAP chloride variants, phase transition temperatures below 0°C are found. For the cooling cycles, this is in each case at -23°C to -24°C. Differences between racemic and enantiomerically pure DOTAP chloride are in each case evident in the heating cycles. (2R)-DOTAP chloride and (2S)-DOTAP both exhibit an endothermic phase transition around -12.5°C, while the phase transition for the race- mate is at -17.5°C (see Fig. 6). Example 4 Transfection properties on COS-7 cells Racemic and enantiomerically pure DOTAP chloride and racemic DOTAP methylsulfate are each dispersed with the same amount of cho- lesterol in the transfection medium and treated with ultrasound. The lipo- somes and GFP plasmid solution are mixed and incubated for 15 min- utes, amounts per 6well: 2 ug of plasmid/8 ug of lipid. After incubation for 5 hrs, the supernatant is removed from the cells by suction at 37°C/5% CO2, 2 ml of fresh medium is added, and the mixture is incubated for a further 20 hours. After work-up, FACS analysis shows efficient transfection for all lipoplexes. A significant difference between the transfection rates for the individual lipid mixtures is evident: (R)-DOTAP chloride/cholesterol complex: 32.4% (S)-DOTAP chloride/cholesterol complex: 11.0% (R,S)-DOTAP chloride/cholesterol complex: 25.9% (R,S)-DOTAP methylsulfate/cholesterol complex: 20.2% WO 2006/056312 PCT/EP2005/011874 - 14- PATENT CLAIMS 1. Crystalline (2R,S)-, (2S)- and (2R)-DOTAP chloride. 2. Crystalline (2R,S)-DOTAP chloride. 3. (2R,S)-DOTAP chloride according to Claim 2 having 2 theta values of 12.6, 19.5, 20.2, 21.5 and 25.2. 4. (2R,S)-DOTAP chloride according to Claim 2 having 2 theta values of 6.5, 12.6, 13.4, 19.5, 20.2, 21.5, 25.2 and 29.8. 5. (2R,S)-DOTAP chloride according to Claim 2 having a spectrum as shown in Fig. 1 (type I) 6. (2R,S)-DOTAP chloride according to Claim 2 having 2 theta values of 3.3, 4.9, 19.3, 20.0 and 23.5. 7. (2R,S)-DOTAP chloride according to Claim 2 having 2 theta values of 3.3, 4.9, 15.1, 16.2, 19.3, 20.0, 23.5 and 24.3. 8. (2R,S)-DOTAP chloride according to Claim 2 having a spectrum as shown in Fig. 2 (type II) 9. (2R,S)-DOTAP chloride according to Claim 2 having 2 theta values of 2.8, 5.8, 20.0, 21.2 and 25.1 10. (2R,S)-DOTAP chloride according to Claim 2 having 2 theta values of 2.8, 5.8, 12.9, 15.9, 20.0, 21.2, 25.1 and 29.4. 11. (2R,S)-DOTAP chloride according to Claim 2 having a spectrum as shown in Fig. 3 (type III) 12. (2S)- and (2R)-DOTAP chloride. 13. Crystalline (2S)- and (2R)-DOTAP chloride. WO 2006/056312 PCT/EP2005/011874 -15- 14. (2S)- and (2R)-DOTAP chloride according to Claim 13 having 2 theta values of 12.8, 19.4, 19.8, 20.2, and 21.5. 15. (2S)- and (2R)-DOTAP chloride according to Claim 13 having 2 theta values of 6.5, 12.8, 19.4, 19.8, 20.2, 20.7, 21.5 and 25.3. 16. (2S)- and (2R)-DOTAP chloride according to Claim 13 having a spectrum as shown in Fig. 4 (type IV) 17. Process for the preparation of crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride, characterised in that the crystallisation is carried out from one or more aprotic solvents. 18. Process for the preparation of crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride according to Claim 17, characterised in that the aprotic solvent employed is an ether selected from the group tetrahydrofuran, methyltetrahydrofuran, dioxane, diethyl ether, dipropyl ether, diisopropyl ether and methyl tert-butyl ether, or a mixture of these ethers. 19. Process for the preparation of crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride according to Claim 17, characterised in that the aprotic solvent employed is a ketone selected from the group acetone, 2-butanone, methyl isobutyl ketone and methyl iso- propyl ketone, or a mixture of these ketones. 20. Process for the preparation of crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride according to Claim 17, characterised in that the aprotic solvent employed is acetonitrile. 21. Process for the preparation of crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride according to Claim 17, characterised in that the solvent employed is an ester selected from the group ethyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, dimethyl carbonate, diethyl carbonate and 1,3-dioxolidin-2-one, or a mixture of these esters. WO 2006/056312 PCT/EP2005/011874 -16- 22. Process according to one or more of Claims 17 to 21, characterised in that an aprotic medium is used in the form of a mixture with an alcohol selected from the group methanol, ethanol, n-propanol, iso- propanol, n-butanol, isobutanol, 2-butanol, tert-butanol, 3-methyl-1- butanol, ethylene glycol, methoxyethanol and ethoxyethanol, or with mixtures thereof. 23. Process according to Claim 17, characterised in that the crystallisa- tion is carried out directly from the reaction solution without prior purification. 24. Process according to Claim 17, characterised in that a recrystallisa- tion of amorphous or crystalline (2R,S)-, (2S)- or (2R)-DOTAP chlo- ride is carried out. 25. Use of crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chlo- ride as constituent for the preparation of medicaments. 26. Use of of (2S)- and (2R)-DOTAP chloride as constituent for the preparation of medicaments. 27. Pharmaceutical composition comprising crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride together with pharmaceuti- cal active compounds, adjuvants or a solvent. 28. Pharmaceutical composition comprising (2R,S)-, (2S)- and (2R)- DOTAP chloride according to Claim 27, characterised in that the pharmaceutical active compound employed is an active compound selected from the group of the peptides, nucleotides, vaccines and cytostatic agents. 29. Pharmaceutical composition comprising crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride according to Claim 27, characterised in that it has liposomes, lipoplexes, nanoparticles or microemulsions. WO 2006/056312 PCT/EP2005/011874 - 17- 30. Pharmaceutical composition comprising (2S)- and (2R)-DOTAP chloride together with pharmaceutical active compounds, adjuvants or a solvent. 31. Pharmaceutical composition comprising (2S)- and (2R)-DOTAP chloride according to Claim 30, characterised in that the pharma- ceutical active compound employed is an active compound se- lected from the group of the peptides, nucleotides, vaccines and cytostatic agents. 32. Pharmaceutical composition comprising (2S)- and (2R)-DOTAP chloride according to Claim 30, characterised in that it has lipo- somes, lipoplexes, nanoparticles or microemulsions. The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R.S)-, (2S)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.

Documents:

02309-kolnp-2007-abstract.pdf

02309-kolnp-2007-claims.pdf

02309-kolnp-2007-correspondence others 1.1.pdf

02309-kolnp-2007-correspondence others.pdf

02309-kolnp-2007-description complete.pdf

02309-kolnp-2007-drawings.pdf

02309-kolnp-2007-form 1.pdf

02309-kolnp-2007-form 2.pdf

02309-kolnp-2007-form 3.pdf

02309-kolnp-2007-form 5.pdf

02309-kolnp-2007-gpa.pdf

02309-kolnp-2007-international publication.pdf

02309-kolnp-2007-other pct form.pdf

02309-kolnp-2007-others.pdf

02309-kolnp-2007-pct request form.pdf

02309-kolnp-2007-priority document.pdf

2268-KOLNP-2014-(29-01-2015)-CORRESPONDENCE.pdf

2309-KOLNP-2007-(29-05-2012)-PETITION UNDER RULE 137.pdf

2309-KOLNP-2007-ABSTRACT.pdf

2309-KOLNP-2007-AMANDED CLAIMS.pdf

2309-KOLNP-2007-CORRESPONDENCE 1.1.pdf

2309-KOLNP-2007-DESCRIPTION (COMPLETE).pdf

2309-KOLNP-2007-DRAWINGS.pdf

2309-KOLNP-2007-FORM 1.pdf

2309-kolnp-2007-form 18.pdf

2309-KOLNP-2007-FORM 2.pdf

2309-KOLNP-2007-FORM 3.pdf

2309-KOLNP-2007-OTHERS 1.1.pdf

2309-KOLNP-2007-OTHERS.pdf

2309-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf